CD40 Ligand Induces an Antileukemia Immune Response In Vivo
Authors:
Open Access
- 1 September 1997
- journal article
- Published by American Society of Hematology in Blood
- Vol. 90 (5) , 1927-1933
Abstract
Leukemia cells may express tumor specific antigens in association with Class I and II major histocompatability complex (MHC) molecules. However, lack of expression of conventional costimulator molecules means that these cells tend to induce specific T-cell anergy rather than activation. CD40 ligand (CD40L) is a costimulator molecule that directly activates T cells and may promote antigen presentation by CD40-expressing cells, which include professional antigen presenting cells and B-acute lymphoblastic leukemia (ALL) cells from many patients. We determined whether transgenic expression of CD40L could enhance an antileukemia immune response using a CD40+ murine lymphoblastic (A20) leukemia and a CD40− myeloblastic (WEHI-3) leukemia in a tumor treatment model. Injection of otherwise nonimmunogenic A20 cells in the presence of CD40L induced an immune response active against preexisting A20 tumor at a distant site. Moreover, concomitant local secretion of transgenic interleukin-2 (IL-2) further amplified the antileukemic response induced and increased protection against preexisting tumor. In ex vivo studies, CD40 activation of A20 cells enhances the antigen presenting potential of A20 cells by upregulating expression of B7.1 (CD80), Class I and II MHC molecules, and increases expression of fas antigens. The importance of CD40 activation to the resulting antitumor response is further emphasized by the failure of transgenic CD40L to protect against the CD40− WEHI myeloblastic leukemia. Depletion studies showed the protective effects against A20 cells to be mediated by a combination of CD4+ and CD8+ T lymphocytes and by natural killer (NK) cells. These results suggest a means by which CD40+ leukemia cells may be rendered immunogenic in vivo.Keywords
This publication has 41 references indexed in Scilit:
- Successful Culture and Selection of Cytokine Gene-Modified Human Dermal Fibroblasts for the Biologic Therapy of Patients with CancerHuman Gene Therapy, 1996
- CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.Journal of Experimental Medicine, 1995
- Role of the CD40‐CD40 ligand interaction in CD4+ T cell contact‐dependent activation of monocyte interleukin‐1 synthesisEuropean Journal of Immunology, 1994
- Activation of human dendritic cells through CD40 cross-linking.Journal of Experimental Medicine, 1994
- Lymphocyte responses and cytokinesCell, 1994
- CD40 ligand is a T cell growth factorEuropean Journal of Immunology, 1993
- Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.Journal of Experimental Medicine, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Molecular and biological characterization of a murine ligand for CD40Nature, 1992
- Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesisNature, 1978